Clinical trials: Non Alcoholic Fatty Liver
Non Alcoholic Fatty Liver Disease, Lifestyle
Non Alcoholic Fatty Liver Disease: Nutritional Epidemiology and Lifestyle Medicine
The study is an open-label intervention non pharmacological Cohort Study without control arm in patients with Non Alcoholic Fatty Liver Disease (NAFLD) and in healthy subjects.
- Conditions
- Non Alcoholic Fatty Liver Disease, Lifestyle, Diet Modification
- Trial name
- SEELN (NCT03300661)
- Testing
- Mediterranean Style
- Where
- Italy
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Università degli Studi di Brescia
Non-alcoholic Steatohepatitis (NASH)
A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients
This study is intended to investigate the safety and tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD2693, following subcutaneous (SC) administration of multiple ascending doses in participants with…
- Trial name
- NCT04483947
- Testing
- AZD2693
- Where
- 16 sites in United States
- Volunteers
- 74 people
- Sponsor
- AstraZeneca
Non-Alcoholic Fatty Liver Disease
Serum Adiponectin as an Early Marker for Renal Impairment in Patients With Non-alcoholic Fatty Liver Disease.
Early detection of renal impairment in patients with non-alcoholic fatty liver disease and its correlation with serum Adiponectin level.
- Trial name
- NCT05106049
- Testing
- serum Adiponectin
- Volunteers
- 90 people
- Sponsor
- Assiut University
Iron, Diabetes
Iron Reduction for the Treatment of Diabetes and Nonalcoholic Fatty Liver Disease
This is a treatment study to determine if reducing the body's iron stores by blood donation will improve diabetes control and other problems associated with diabetes such as fatty liver disease.
- Conditions
- Iron, Diabetes, Nonalcoholic Fatty Liver
- Trial name
- NCT03696797
- Testing
- Blood Donation
- Where
- 2 sites in United States
- Volunteers
- 132 people
- Sponsor
- Wake Forest University Health Sciences
COVID-19
Mapping Organ Health Following COVID-19 Disease Due to SARS-CoV-2 Infection
A prospective, longitudinal, observational cohort study looking at patients following COVID-19 disease using multi-parametric magnetic resonance imaging (MRI) to assess the degree and prevalence of organ injury.
- Trial name
- COVERSCAN (NCT04369807)
- Testing
- Outpatient MRI
- Where
- 2 sites in United Kingdom
- Volunteers
- 693 people
- Sponsor
- Perspectum
Non-alcoholic Fatty Liver, Atherogenic Dyslipidemia
Genetic Pathways Leading to Fatty Liver and Atherogenic Dyslipidemia
The aims of the study are: 1. To investigate if carriers of apolipoprotein (apo) CIII loss-of-function (LOF) mutations produce less apo-CIII that results in reduction of large very low-density lipoprotein (VLDL) particle…
- Conditions
- Non-alcoholic Fatty Liver, Atherogenic Dyslipidemia, Insulin Resistance
- Trial name
- VARKIN (NCT04209816)
- Testing
- Lipoprotein kinetics
- Where
- 2 sites in Finland, Sweden
- Volunteers
- 100 people
- Sponsor
- Marja-Riitta Taskinen
Nonalcoholic Fatty Liver Disease
Diabetes Prevention Program for the Treatment of Nonalcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease (NAFLD) is a rapidly growing epidemic worldwide and is an increasingly important etiology of chronic liver disease and hepatocellular carcinoma.
- Trial name
- NCT04988204
- Testing
- Diabetes Prevention Program
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
NASH With Fibrosis
Single Dose ADME Study of [14C]-Rencofilstat in Healthy Male Subjects
This is a single-center, single-period, single-dose, open-label, non-randomized study to assess the mass balance recovery, metabolite profile and metabolite identification of 14C- labelled rencofilstat ([14C] CRV431).
- Trial name
- NCT05737433
- Testing
- [14C]-rencofilstat 225mg
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Hepion Pharmaceuticals, Inc.
NAFLD (Nonalcoholic Fatty Liver Disease), Polycystic Ovarian Syndrome (PCOS)
PolyCystic Ovary Syndrome as Suggested Risk Group for Non-Alcoholic Fatty Liver Disease
To study the prevalence, non-invasive diagnostics and evolution of non-alcoholic-fatty-liver-disease (NAFLD) in patients with polycystic ovary syndrome (PCOS)
- Trial name
- P-CORIGA (NCT07146815)
- Testing
- FibroScan, MRI PDFF
- Where
- Belgium
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- Ziekenhuis Oost-Limburg
Fatty Liver Disease
A Clinical Study of Ultrasound-derived Fat Fraction to Assess Metabolic Dysfunction-Associated Steatotic Liver Disease
Aims: To evaluate the diagnostic performance of ultrasound-derived fat fraction (UDFF) in assessing the degree of hepatic steatosis in an obese population, with liver biopsy as reference standard.
- Trial name
- NCT06487325
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Ma Zhe
Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
The purpose of this study is to evaluate the safety and efficacy of cotadutide in participants with non-cirrhotic NASH with fibrosis.
- Trial name
- PROXYMO-ADV (NCT05364931)
- Testing
- Cotadutide
- Where
- 115 sites in United States, Argentina and 18 more
- Volunteers
- 54 people
- Sponsor
- AstraZeneca
NASH - Nonalcoholic Steatohepatitis, NAFLD
Characterization of the Platelet Inflammatory Response in NAFL and NASH
The primary objective of the study is to identify which features of platelet activation promote the inflammatory response that underlies the progression from NAFL to NASH. Therefore, the investigators plan: 1.
- Trial name
- NCT05128253
- Testing
- High fat meal in a subset of patients with NAFL or NASH
- Where
- 2 sites in Italy
- Volunteers
- 44 people
- Sponsor
- Stefania Basili
Liver Diseases, Primary Biliary Cirrhosis
Repeatability and Reproducibility of Multiparametric MRI
This study aims to prospectively assess the repeatability and reproducibility of iron-corrected T1 (cT1), T2*, and hepatic proton density fat fraction (PDFF) quantification with multiparametric MRI using the LiverMultiScan™ (LMS…
- Conditions
- Liver Diseases, Primary Biliary Cirrhosis, Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
- Trial name
- NCT03743272
- Testing
- LiverMultiScan
- Where
- 4 sites in Netherlands, United Kingdom
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Perspectum
Non-alcoholic Steatohepatitis (NASH)
A Research Study Looking Into Blood and Urine Levels of the Medicine NNC0194-0499 in the Body and How Well it is Tolerated in Participants With Reduced Kidney Function and Normal Kidney Function
Novo Nordisk is developing the study medicine NNC0194-0499 for the treatment of non-alcoholic steatohepatitis (NASH). NASH is a serious disease where fat, inflammation and scar tissue builds up in the liver.
- Trial name
- NCT05727644
- Testing
- NNC0194-0499
- Where
- Germany
- Volunteers
- 42 people
- Sponsor
- Novo Nordisk A/S
Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis
Plant Stanols and Liver Inflammation in Overweight and Obese Children
Obesity is associated with a variety of co-morbidities. Children with obesity are more likely to have risk factors associated with cardiovascular diseases (CVD) and CVD risk markers (e.g.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis, NAFLD, NASH
- Trial name
- NCT04783116
- Testing
- Plant stanols (3g/day)
- Where
- Netherlands
- Volunteers
- 52 people
- Sponsor
- Maastricht University Medical Center
NAFLD (Nonalcoholic Fatty Liver Disease)
Evaluating the Safety and Efficacy of Roflumilast in the Treatment of Nonalcoholic Fatty Liver Disease Patients
Nonalcoholic fatty liver disease (NAFLD) is a global public health concern, and the leading cause of chronic liver disease, especially in developed countries.
- Trial name
- NCT07900087
- Testing
- Roflumilast
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Tanta University
Nonalcoholic Fatty Liver, Metabolic Syndrome
Molecules Associated With the Presence and Severity of Nonalcoholic Fatty Liver Disease
Non-invasive diagnosis and treatment of nonalcoholic fatty liver disease (NAFLD) remain unmet medical needs. Aim of this study is to investigate the blood levels of three hormonal systems related to obesity, insulin resistance…
- Trial name
- NAFLD (NCT03986684)
- Where
- Greece
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Hippocration General Hospital
Non-alcoholic Fatty Liver Disease
Study of Changes in Hepatic Fat Following Administration of MK-4074 and Pioglitazone Hydrochloride (MK-4074-008)
This study will evaluate changes in liver fat content following multiple oral doses of MK-4074 and Pioglitazone Hydrochloride in adult males and females with fatty liver disease.
- Trial name
- NCT01431521
- Testing
- MK-4074 200 mg, Pioglitazone hydrochloride 30 mg
- Volunteers
- 31 people
- Sponsor
- Merck Sharp & Dohme LLC
Liver Diseases, Hypertension, Portal
A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)
This study is open to adults with liver cirrhosis caused by hepatitis B, hepatitis C or nonalcoholic steatohepatitis (NASH). People can join this study if they have high blood pressure in the portal vein (main vessel going to the…
- Trial name
- NCT05282121
- Testing
- Avenciguat, Empagliflozin
- Where
- 31 sites in United States, Argentina and 14 more
- Volunteers
- 90 people
- Sponsor
- Boehringer Ingelheim
Non-Alcoholic Steatohepatitis
The Effect of Aerobic and Resistant Exercise Training in Patients With Non-Alcoholic Steatohepatitis
The term non-alcoholic fatty liver disease (NAFLD) is used to describe a range of chronic liver diseases that range from steatosis to steatohepatitis, advanced fibrosis, cirrhosis, or excessive alcohol consumption or other causes…
- Trial name
- NCT05065593
- Testing
- resistance and aerobic exercise, physical activity recommendation
- Where
- Turkey (Türkiye)
- Volunteers
- 26 people
- Sponsor
- Hacettepe University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.